Abstract
T cells engineered to express antigen-specific T cell receptors (TCRs) are potent therapies for viral infections and cancer. However, efficient identification of clinical candidate TCRs is complicated by the size and complexity of T cell repertoires and the challenges of working with primary T cells. Here we present a high-throughput method to identify TCRs with high functional avidity from diverse human T cell repertoires. The approach used massively parallel microfluidics to generate libraries of natively paired, full-length TCRαβ clones, from millions of primary T cells, which were then expressed in Jurkat cells. The TCRαβ–Jurkat libraries enabled repeated screening and panning for antigen-reactive TCRs using peptide major histocompatibility complex binding and cellular activation. We captured more than 2.9 million natively paired TCRαβ clonotypes from six healthy human donors and identified rare (<0.001% frequency) viral-antigen-reactive TCRs. We also mined a tumor-infiltrating lymphocyte sample from a patient with melanoma and identified several tumor-specific TCRs, which, after expression in primary T cells, led to tumor cell killing.
Original language | English |
---|---|
Pages (from-to) | 609-619 |
Number of pages | 11 |
Journal | Nature biotechnology |
Volume | 38 |
Issue number | 5 |
DOIs | |
Publication status | Published - 16 Mar 2020 |
Research Beacons, Institutes and Platforms
- Manchester Cancer Research Centre
Fingerprint
Dive into the research topics of 'Massively parallel interrogation and mining of natively paired human TCRαβ repertoires'. Together they form a unique fingerprint.Impacts
-
Commercial Development and Patient Benefit of Adoptive Cell Therapy (ACT) for Cancer
Thistlethwaite, F. (Corresponding participant), Hawkins, R. (Participant), Stern, P. (Participant) & Gilham, D. (Participant)
Impact: Technological impacts, Health and wellbeing, Economic, Policy